Elevated serum vancomycin concentrations after oral administration in a hemodialysis patient with pseudomembranous colitis

Japanese Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 3, 2003, Pages 87-90

  Hirata, Sumio ^a   Matoba, Mami ^a   Izumi, Satoshi ^a   Furukubo, Taku ^a   Ota, Miyuki ^a   Fujita, Minori ^a   Okuno, Senji ^a   Yamakawa, Tomoyuki ^a  

^a OSAKA CITY UNIVERSITY   (Japan)

Author keywords

Clostridium difficile; Pharmacokinetics; Pseudomembranous colitis; Vancomycin

Indexed keywords

CALCIUM CARBONATE; CEFOTIAM; CEFTAZIDIME; CLINDAMYCIN; FAMOTIDINE; INSULIN; LEVOFLOXACIN; METRONIDAZOLE; VANCOMYCIN;

AGED; ARTICLE; BRONCHITIS; CASE REPORT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; ENTEROPATHY; HEMODIALYSIS; HUMAN; INTESTINE ABSORPTION; KIDNEY FAILURE; MALE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMEMBRANOUS COLITIS; SIDE EFFECT;

EID: 0037787759     PISSN: 03881601     EISSN: None     Source Type: Journal    
DOI: 10.3999/jscpt.34.3_87     Document Type: Article

References (15)

1. Geraci JE, Heilman FR, Nichols DR, Wellman WE, Ross GT. Some laboratory and clinical experiences with a new antibiotic, vancomycin, In. Antibiotics Annual. NY: Medical Encyclopedia, 1956-1957: 90-106.
2. Thompson CM Jr, Long SS, Gilligan PH, Prebis JW. Absorption of oral vancomycin possible associated toxicity. Int J Pediatr Nephrol 1983; 4: 1-4.
3. Spitzer PG, Eliopoulos GM. Systemic absorption of enterel vancomycin in a patient with pseudmembranous colitis Ann Int Med 1984; 100: 533-4.
4. Matzke GR, Halstenson CE, Olson PL, Collins AJ, Abraham PA. Sysemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis 1987; 9: 422-5.
5. Adachi M, Hirata S, Izumi S, Ota M. Kim M, Tanaka K. Dosage recommendation of vancomycin in patients with type II dialyzer membrane. J Jpn Soc Dial Ther 2001; 34 supple 1: 662. (in Japanese)
6. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 1978; 29: 226-8.
7. Dudley MN, Quintiliani R, Nightingale CH, Gontarz N. Absorption of vancomycin. Ann Intern Med 1984; 101: 144.
8. Nagata H, Higashiyama I, Kondoh R, Komatsu Y. In vitro antibacterial activity of vancomycin. Chemotherapy 1992; 40: 581-91.
9. Moyenuddin M, Williamson JC, Ohl CA. Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy. Curr Gastroenterol Rep 2002; 4: 279-86.
10. Hecht JR, Olinger EJ. Clostridium difficile colitis secondary to intravenous vancomycin. Digestive Dis Sci 1989; 34: 148-9.
11. Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 1998; 13: 2842-6.
12. Barany P, Stenvinkell P, Nord CE, Bergstrom J. Clostridium difficile infection - a poor prognostic sign in uremic patients? Clin Nephrol 1992; 38: 53-7.
13. The United States Pharmacopeial Convention. Authority of the United States Pharmacopeial Convention, Willston. Drug Information for the Health Care Professional vol I, 28th ed. Willstone: US Pharmacopeia, 1998: 2930-2.
14. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GA. Randomised controlled trial of vancomycin for pseudmembranous colitis and postoperative dairrhoea. Brit Med J 1978; 2: 1667-9.
15. Dollery C (Ed.). Therapeutic drugs, 2nd ed. London: Churchill Livingstone, 1999: V6-V10.